David E. Avigan, MD, is a Professor of Medicine at Harvard Medical School, Boston, MA. He is Chief of the Hematology and Hematologic Malignancies Division at the Beth Israel Deaconess Medical Center and is also a member of the Dana-Farber/Harvard Cancer Center (DF/HCC) programs on leukemia, lymphoma, and myeloma and Deputy Associate Director of Clinical Science in DF/HCC associations.
Prof. Avigan received his medical degree from the School of Medicine at Yale University in 1989. He did his first residency in internal medicine at the Columbian Presbyterian Medical Center (1990-1992) and a second residency in the same institution from 1992 and 1993. From 1993 to 1996 he undertook a fellowship at the Memorial Sloan-Kettering Cancer Center in the area of Hematology and Oncology. He is certified by the American Board of Internal Medicine in internal medicine, hematology, medical oncology.
Speaking on lymphoma, myeloma, and leukemia
Prof. Avigan’s research focuses on hematological malignancies including multiple myeloma, lymphoma, and leukemia. He is interested in cellular therapy and immunotherapy approaches as applied in the field of bone marrow transplant. Specifically, his group is working on the development of cancer vaccines and new practices in allogeneic transplantation.